COPD market to expand with AstraZeneca’s focus on biologics and strong portfolio growth
AstraZeneca’s Fasenra, an IL-5-targeting monoclonal antibody already approved for asthma, represents a promising contender ...
Future Market Insights4d
Global Short-Acting Beta-Agonists Market Projected to Reach USD 1759.45 Million by 2033 with a robust CAGR of 9.1%
Increasing Prevalence of Asthma and COPD: The rising incidence of asthma and chronic obstructive pulmonary disease (COPD) ...